|
|
|
| home > white papers > Case Study: Getting the Client’s Trust - Oncology Program - Cmed Clinical Services |
|
|
 WHITE PAPERS |
|
Cmed Clinical Services
|
|
Case Study: Getting the Client’s Trust - Oncology Program
|
|
Five years ago, a biopharmaceutical company chose Cmed to conduct a
phase II oncology study. Cmed’s performance of the study and the good
relationship established with the Client led Cmed to be awarded a second
oncology trial which a couple of years ago was followed by a third,
fourth and fifth.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group
Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that
has developed and is commercialising single cell analysis systems
underpinned by its proprietary picodroplet technology, announced today
that it has closed a $40 million (circa £30 million) investment round.
The round was led by Sofinnova Partners (Paris, France) and Redmile
Group (San Francisco, USA) co-investing on equal terms.
More info >> |
|
 |
White Papers |
 |
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
RSSL
Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >> |
|
|
|
